6505--ME/ New Pluvicto Theronastic Therapy Radiopharmaceuticals/STL(VA-26-00053903) 657-26-4-1642-0063

SOL #: 36C25526Q0334Sources Sought

Overview

Buyer

Veterans Affairs
Veterans Affairs, Department Of
255-NETWORK CONTRACT OFFICE 15 (36C255)
LEAVENWORTH, KS, 66048, United States

Place of Performance

St. Louis, Missouri

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Timeline

1
Posted
Apr 15, 2026
2
Response Deadline
Apr 22, 2026, 8:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The VA Heartland Network 15 is conducting market research (Sources Sought) to identify qualified firms capable of providing the radiopharmaceutical agent Pluvicto for the St. Louis VA Medical Center. This agent (Lutetium LU 177 Vipivvotide Tetraxetan) is used for treating PSMA-positive metastatic castration-resistant prostate cancer and for diagnostic imaging. Responses are due April 23, 2026.

Scope of Work

The requirement is for the provision of the proprietary radiopharmaceutical agent Pluvicto (NDC Code: 69488-0010-61). This agent is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer who have undergone androgen receptor pathway inhibition and taxane-based chemotherapy. It is also used as a radioactive diagnostic therapy radiopharmaceutical for PSMA-positive lesions in men with suspected metastasis or recurrence. Nuclear Medicine will administer these agents via IV.

Contract Details

  • Type: Sources Sought / Market Research (for planning purposes only)
  • Anticipated Contract: 1-year Blanket Purchase Agreement (BPA)
  • NAICS Code: 325412 Pharmaceutical Preparation Manufacturing
  • Place of Performance: St. Louis VA Medical Center, St. Louis, Missouri
  • Published: April 15, 2026

Set-Aside & Eligibility

  • Anticipated Set-Aside: Total Service-Disabled Veteran Owned Small Business (SDVOSB) based on Public Law 109-461, Section 8127. If SDVOSB responses are insufficient, an alternate set-aside or full and open competition may be considered.
  • Registration: Offerors must be registered in SAM.gov. SDVOSB/VOSB firms must also be registered with the SBA's Veteran Small Business Certification (VetCert) Registry.

Submission Requirements

  • This is not a solicitation; no contract will be awarded based on responses, and no payment for submission costs.
  • Responses must include: company name, address, point of contact, phone, fax, email, Unique Entity ID (UEI), Cage Code, Tax ID Number, type of small business (e.g., SDVOSB, VOSB, 8(a), HUBZone, WOSB), and a capability statement detailing qualifications.
  • Submission Deadline: April 23, 2026, 3:00 PM CST
  • Submission Method: Email to Michael.murphy7@va.gov
  • Subject Line: Reference "36C255-26-Q-0334 PLUVICTO"

Additional Notes

The government is not obligated to issue a solicitation or award a contract based on this notice.

People

Points of Contact

Michael MurphyContracting OfficerPRIMARY

Files

Files

Download

Versions

Version 1Viewing
Sources Sought
Posted: Apr 15, 2026
6505--ME/ New Pluvicto Theronastic Therapy Radiopharmaceuticals/STL(VA-26-00053903) 657-26-4-1642-0063 | GovScope